Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase I study of the ALK/FAK/Pyk2 inhibitor CT-707 in patients with ALK-positive
non-small cell lung cancer.
The purpose of the study is to determine the MTD/RP2D of CT-707 and evaluate whether CT-707
is safe and has beneficial effects in ALK-positive advanced non-small cell lung cancer.